Aura Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AURA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
16 Apr 25	SellUS$4,925	Amy Elazzouzi	Individual	897	US$5.49
16 Apr 25	SellUS$39,319	Conor Kilroy	Individual	7,162	US$5.49
18 Feb 25	SellUS$16,670	Mark Plavsic	Individual	2,151	US$7.75
18 Feb 25	SellUS$10,881	Amy Elazzouzi	Individual	1,404	US$7.75
18 Feb 25	SellUS$19,639	Jill Hopkins	Individual	2,534	US$7.75
18 Feb 25	SellUS$156,796	Elisabet de los Pinos	Individual	20,221	US$7.75
21 Jan 25	SellUS$122,381	Elisabet de los Pinos	Individual	15,955	US$7.67
21 Jan 25	SellUS$7,679	Amy Elazzouzi	Individual	1,001	US$7.67
18 Nov 24	SellUS$110,663	Jill Hopkins	Individual	11,822	US$9.36
29 Oct 24	SellUS$5,938	Amy Elazzouzi	Individual	553	US$10.74
29 Oct 24	SellUS$98,788	Elisabet de los Pinos	Individual	9,200	US$10.74
16 Oct 24	SellUS$72,723	Mark Plavsic	Individual	7,383	US$9.85

Insider Trading Volume

Insider Buying: AURA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AURA?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	850,639	1.69%
VC/PE Firms	3,039,892	6.05%
General Public	5,038,913	10%
Hedge Funds	17,399,088	34.6%
Institutions	23,896,780	47.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 84.57% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
13.8%	Matrix Capital Management Company, LP	6,922,870	US$42.6m	0%	5.45%
9.72%	Adage Capital Management, L.P.	4,881,125	US$30.0m	0%	0.05%
8.12%	Eventide Asset Management, LLC	4,080,605	US$25.1m	-29.7%	0.45%
7.05%	BlackRock, Inc.	3,539,948	US$21.8m	-0.32%	no data
6.09%	Suvretta Capital Management, LLC	3,057,319	US$18.8m	0%	0.74%
6.05%	Medicxi Ventures (UK) LLP	3,039,892	US$18.7m	0%	4.79%
5.05%	Long Focus Capital Management LLC	2,537,774	US$15.6m	124%	1.25%
3.82%	The Vanguard Group, Inc.	1,917,730	US$11.8m	6.22%	no data
3.48%	Lundbeckfonden BioCapital	1,750,108	US$10.8m	0%	0.19%
3.43%	Franklin Resources, Inc.	1,722,619	US$10.6m	3.22%	no data
2.53%	Nantahala Capital Management, LLC	1,270,035	US$7.8m	0%	0.58%
2.48%	Levin Capital Strategies, L.P.	1,247,619	US$7.7m	202%	0.74%
2.02%	Geode Capital Management, LLC	1,012,799	US$6.2m	0.39%	no data
1.6%	State Street Global Advisors, Inc.	801,823	US$4.9m	6.23%	no data
1.37%	UBS Asset Management AG	687,322	US$4.2m	3,030%	no data
1.21%	Regency Capital Management Inc.	609,424	US$3.7m	-8.67%	2.0%
1.11%	T. Rowe Price Group, Inc.	556,941	US$3.4m	7.91%	no data
1.03%	Decheng Capital LLC	515,555	US$3.2m	0%	0.7%
0.94%	The B Group, Inc.	472,576	US$2.9m	0%	2.38%
0.78%	Ensign Peak Advisors, Inc.	390,695	US$2.4m	43.3%	no data
0.77%	Northern Trust Global Investments	387,269	US$2.4m	6.32%	no data
0.73%	Dimensional Fund Advisors LP	365,824	US$2.2m	25%	no data
0.57%	David Johnson	285,667	US$1.8m	0%	no data
0.43%	Elisabet de los Pinos	214,156	US$1.3m	19.6%	no data
0.42%	Mark Plavsic	209,456	US$1.3m	72.9%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 20:46
End of Day Share Price	2025/05/02 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Wolleben	Citizens JMP Securities, LLC
Liisa Bayko	Evercore ISI
Edward White	H.C. Wainwright & Co.